Efficacy and safety of donafenib combined with TACE or HAIC in the treatment of hepatocellular carcinoma
Latest Information Update: 03 Jan 2025
At a glance
- Drugs Donafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Results(n=36) assessing the efficacy of donafenib combined with TACE , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2024 New trial record